LLY
Eli Lilly and Company
904.97
-
1.21
0.13%
9 x 904.60
8 x 908.00
bid
ask
9 @ 04:00 PM
907.44+2.47 (0.27%)
Bearish
79
Bullish
132
sentiment
903.46
day range
915.50
516.57
52 week range
972.53
Prev Close906.18
Open906.31
Low903.46
High915.50
Volume1.77M
Avg. Volume3.18M
Market Cap814.86B
Inst. Own83.53%
Beta0.42
Short Ratio1.75
Div & Yield5.20 / 0.57
EPS8.16
P/E110.90
1yr Target1003.35
50day MA896.11
200day MA776.94
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | 4.53 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 2.64 | 3.92 | 1.28 | 48.48% |
2024-04-30 | 2024-03 | 2.53 | 2.58 | 0.05 | 1.98% |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-09-15 | ALVAREZ RALPH | Director | 54.25K | Stock Award(Grant) |
2024-08-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Gift |
2024-09-15 | HEDLEY MARY LYNNE | Director | 1.64K | Stock Award(Grant) |
2024-09-15 | JOHNSON KIMBERLY H | Director | 2.69K | Stock Award(Grant) |
2024-09-02 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 96.89M | Sale |
2024-09-15 | LUCIANO JUAN R | Director | 15.81K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend
...
Dividend | Date |
---|---|
1.3 | 2024-08-15 |
1.3 | 2024-05-15 |
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
Split
...
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
Eli Lilly to enter licence agreement for novel CX3CR1 inhibitor, undertake responsibility for clinical development, commercialization?
-
Sorrento therapeutics
-
Less dose! 10times as potent ! Don’t need infusion
-
Sorrento is better
-
-
-
My hospital is pumping this med $LLY gonna be a billionaire beat
-
They know Sorrento is better and less dosage
-
But $SRNE has the most Potent cocktail
-
Hmmmm something is going to blow
-
Regeneron already has rights to it
-
Maybe lily owns the bar but sell srne?
-
But $SRNE has a better cocktail???????
-
$SRNE is a better product
-
-
-
-
ResMed stock cut at Wolfe on Lilly GLP-1 threat (NYSE:RMD)
news.google.com • -
December 20th Options Now Available For Eli Lilly (LLY)
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Looking Into Eli Lilly's Recent Short Interest
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
Lilly Gets FDA Approval for Eczema Drug Ebglyss
zacks.com • -
Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025
news.google.com • -
(LLY) Long Term Investment Analysis
news.google.com • -
Do queasy side effects mean the end of weight-loss drug stock hype?
news.google.com • -
Is Eli Lilly and Company (LLY) an Unstoppable Dividend Stocks to Buy?
news.google.com • -
Eli Lilly and Co (LLY) Stock Price, Trades & News
news.google.com • -
Eli Lilly stock gains as Citi resumes at buy (NYSE:LLY)
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
news.google.com • -
Bull of the Day: Eli Lilly (LLY)
news.google.com •